首页>
中文期刊>
《癌症生物学与医学：英文版》
>Polymorphisms of ERCC1, XPD, XRCC1 and XPG Predict Clinical Outcome in Advanced Gastric Cancer Patients Receiving Oxaliplatin-Based Chemotherapy in Chinese Population
Polymorphisms of ERCC1, XPD, XRCC1 and XPG Predict Clinical Outcome in Advanced Gastric Cancer Patients Receiving Oxaliplatin-Based Chemotherapy in Chinese Population
OBJECTIVE To investigate whether polymorphisms in ERCC1,XPD,XPG,XRCC1 genes are associated with clinical outcomes inadvanced gastric cancer (AGC) patients treated with oxaliplatin-based chemotherapy.METHODS The genetic polymorphisms in ERCC1,XPD,XPG,XRCC1 were determined in 94 advanced gastric cancer patientstreated with oxaliplatin-based chemotherapy,using TaqMan-MGBprobes.The clinical response of 60 patients with stage Ⅳ disease,time to progression (TTP) and overall survival (OS) of 94 patientswere evaluated.RESULTS The overall disease control rate (CR + PR + SD) of the60 patients in stage Ⅳ was 70% (42/60).Patients with XRCC1 399G/G,XPG 46 C/C genotypes showed enhanced response to theoxaliplatin-based chemotherapy compared to those with othergenotypes (P0.05).CONCLUSION Testing for XRCC1 399,XPG 46 polymorphismsmay allow identification of the gastric cancer patients whowill benefit from oxaliplatin-based chemotherapy.Specificpolymorphisms may influence clinical outcomes of AGCpatients.Selecting specific chemotherapy based on pretreatmentgenotyping represents an innovative strategy that warrantsprospective studies.
展开▼
机译：Genetic association of rs7754840 and rs7756992 polymorphisms in the CDKAL1 gene and gestational diabetes mellitus in selected Filipino pregnant women
机译：Interferon Regulatory Factor 5 and Renin-Angiotensin-Aldosterone System Polymorphisms in Coronary Artery Disease: An Overview of Experimental and Clinical Studies
机译：Withdrawn: Associations of candidate gene polymorphisms with poor responsiveness to aspirin: A meta‐analysis. Shen Jiang, Ying Yue, Chaolun Gou, Shan Hu and Yanhua Tang
